Elucidating Distinct Roles for NF1 in Melanomagenesis

Cancer Discovery - Tập 3 Số 3 - Trang 338-349 - 2013
Ophélia Maertens1,2,3,4,5,6,7, Bryan W. Johnson1,2,3,4,5,6,7, Pablo E. Hollstein1,2,3,4,5,6,7, Dennie T. Frederick1,8,2,3,4,5,6,7, Zachary A. Cooper1,8,2,3,4,5,6,7, Ludwine Messiaen1,8,2,3,4,5,6,7, Roderick T. Bronson1,8,2,3,4,5,6,7, Martin McMahon1,2,3,4,5,6,7, Scott R. Granter1,2,3,4,5,6,7, Keith T. Flaherty1,8,2,3,4,5,6,7, Jennifer A. Wargo1,8,2,3,4,5,6,7, Richard Marais1,8,2,3,4,5,6,7, Karen Cichowski1,2,3,4,5,6
1Authors' Affiliations: 1Genetics Division, Department of Medicine, 2Department of Pathology, Brigham and Women's Hospital; 3Harvard Medical School; 4Divisions of Surgical Oncology and Medical Oncology and Department of Dermatology, Massachusetts General Hospital; 5Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; 6Department of Genetics, Medical Genomics Laboratory, University of Alabama at Birmingham, Birmingham, Alabama; 7Cancer Research Institute; 8Department of Cell and Molecular Pharmacology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and 9The Paterson Institute for Cancer Research, The University of Manchester, Manchester, United Kingdom
2Cancer Research Institute
3Department of Genetics, Medical Genomics Laboratory, University of Alabama at Birmingham, Birmingham, Alabama
4Divisions of Surgical Oncology and Medical Oncology and Department of Dermatology, Massachusetts General Hospital
5Harvard Medical School
6Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts
7The Paterson Institute for Cancer Research, The University of Manchester, Manchester, United Kingdom
8Authors' Affiliations:Genetics Division, Department of Medicine, Department of Pathology, Brigham and Women's Hospital

Tóm tắt

Abstract BRAF mutations play a well-established role in melanomagenesis; however, without additional genetic alterations, tumor development is restricted by oncogene-induced senescence (OIS). Here, we show that mutations in the NF1 tumor suppressor gene cooperate with BRAF mutations in melanomagenesis by preventing OIS. In a genetically engineered mouse model, Nf1 mutations suppress Braf-induced senescence, promote melanocyte hyperproliferation, and enhance melanoma development. Nf1 mutations function by deregulating both phosphoinositide 3-kinase and extracellular signal–regulated kinase pathways. As such, Nf1/Braf–mutant tumors are resistant to BRAF inhibitors but are sensitive to combined inhibition of mitogen-activated protein/extracellular signal–regulated kinase kinase and mTOR. Importantly, NF1 is mutated or suppressed in human melanomas that harbor concurrent BRAF mutations, NF1 ablation decreases the sensitivity of melanoma cell lines to BRAF inhibitors, and NF1 is lost in tumors from patients following treatment with these agents. Collectively, these studies provide mechanistic insight into how NF1 cooperates with BRAF mutations in melanoma and show that NF1/neurofibromin inactivation may have an impact on responses to targeted therapies. Significance: This study elucidates the mechanism by which NF1 mutations cooperate with different BRAF mutations in melanomagenesis and shows that NF1/neurofibromin loss may desensitize tumors to BRAF inhibitors. Cancer Discov; 3(3); 338–49. ©2012 AACR. See related commentary by Gibney and Smalley, p. 260 This article is highlighted in the In This Issue feature, p. 239

Từ khóa


Tài liệu tham khảo

Courtois-Cox, 2008, Many roads lead to oncogene-induced senescence, Oncogene, 27, 2801, 10.1038/sj.onc.1210950

Kuilman, 2010, The essence of senescence, Genes Dev, 24, 2463, 10.1101/gad.1971610

Bartkova, 2006, Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints, Nature, 444, 633, 10.1038/nature05268

Di Micco, 2006, Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication, Nature, 444, 638, 10.1038/nature05327

Mallette, 2007, The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence, Genes Dev, 21, 43, 10.1101/gad.1487307

Narita, 2003, Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence, Cell, 113, 703, 10.1016/S0092-8674(03)00401-X

Courtois-Cox, 2006, A negative feedback signaling network underlies oncogene-induced senescence, Cancer Cell, 10, 459, 10.1016/j.ccr.2006.10.003

Wajapeyee, 2008, Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7, Cell, 132, 363, 10.1016/j.cell.2007.12.032

Acosta, 2008, Chemokine signaling via the CXCR2 receptor reinforces senescence, Cell, 133, 1006, 10.1016/j.cell.2008.03.038

Kuilman, 2008, Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network, Cell, 133, 1019, 10.1016/j.cell.2008.03.039

Gray-Schopfer, 2006, Cellular senescence in naevi and immortalisation in melanoma: a role for p16?, Br J Cancer, 95, 496, 10.1038/sj.bjc.6603283

Michaloglou, 2005, BRAFE600-associated senescence-like cell cycle arrest of human naevi, Nature, 436, 720, 10.1038/nature03890

Garnett, 2004, Guilty as charged: B-RAF is a human oncogene, Cancer Cell, 6, 313, 10.1016/j.ccr.2004.09.022

Dankort, 2009, Braf(V600E) cooperates with Pten loss to induce metastatic melanoma, Nat Genet, 41, 544, 10.1038/ng.356

Dhomen, 2009, Oncogenic Braf induces melanocyte senescence and melanoma in mice, Cancer Cell, 15, 294, 10.1016/j.ccr.2009.02.022

Pollock, 2003, High frequency of BRAF mutations in nevi, Nat Genet, 33, 19, 10.1038/ng1054

Vredeveld, 2012, Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis, Genes Dev, 26, 1055, 10.1101/gad.187252.112

Bernards, 2005, GAPs in growth factor signalling, Growth Factors, 23, 143, 10.1080/08977190500130480

Dasgupta, 2005, Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors, Cancer Res, 65, 2755, 10.1158/0008-5472.CAN-04-4058

Johannessen, 2005, The NF1 tumor suppressor critically regulates TSC2 and mTOR, Proc Natl Acad Sci U S A, 102, 8573, 10.1073/pnas.0503224102

Cancer Genome Atlas Research Network, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385

Ding, 2008, Somatic mutations affect key pathways in lung adenocarcinoma, Nature, 455, 1069, 10.1038/nature07423

McGillicuddy, 2009, Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis, Cancer Cell, 16, 44, 10.1016/j.ccr.2009.05.009

Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126/science.1164382

Holzel, 2010, NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome, Cell, 142, 218, 10.1016/j.cell.2010.06.004

Bosch, 1997, Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1, Oncogene, 15, 1021, 10.1038/sj.onc.1201270

Zhu, 1998, Senescence of human fibroblasts induced by oncogenic Raf, Genes Dev, 12, 2997, 10.1101/gad.12.19.2997

Woods, 1997, Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1, Mol Cell Biol, 17, 5598, 10.1128/MCB.17.9.5598

De Schepper, 2005, Pigment cell-related manifestations in neurofibromatosis type 1: an overview, Pigment Cell Res, 18, 13, 10.1111/j.1600-0749.2004.00206.x

Zhu, 2001, Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain, Genes Dev, 15, 859, 10.1101/gad.862101

Dankort, 2007, A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors, Genes Dev, 21, 379, 10.1101/gad.1516407

Bosenberg, 2006, Characterization of melanocyte-specific inducible Cre recombinase transgenic mice, Genesis, 44, 262, 10.1002/dvg.20205

Ramjaun, 2007, Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis, Cell Cycle, 6, 2902, 10.4161/cc.6.23.4996

Johannessen, 2008, TORC1 is essential for NF1-associated malignancies, Curr Biol, 18, 56, 10.1016/j.cub.2007.11.066

Ji, 2012, Targeting the RAS pathway in melanoma, Trends Mol Med, 18, 27, 10.1016/j.molmed.2011.08.001

Bollag, 2010, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, 467, 596, 10.1038/nature09454

De Raedt, 2011, Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors, Cancer Cell, 20, 400, 10.1016/j.ccr.2011.08.014

Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040

Lin, 2008, Modeling genomic diversity and tumor dependency in malignant melanoma, Cancer Res, 68, 664, 10.1158/0008-5472.CAN-07-2615

Smalley, 2009, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations, Oncogene, 28, 85, 10.1038/onc.2008.362

Guldberg, 1997, Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma, Cancer Res, 57, 3660

Johannessen, 2010, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature, 468, 968, 10.1038/nature09627

Nazarian, 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626

Poulikakos, 2011, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, 480, 387, 10.1038/nature10662

Shi, 2012, Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance, Nat Commun, 3, 724, 10.1038/ncomms1727

Villanueva, 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K, Cancer Cell, 18, 683, 10.1016/j.ccr.2010.11.023

Paraiso, 2011, PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression, Cancer Res, 71, 2750, 10.1158/0008-5472.CAN-10-2954

Shao, 2010, Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells, Cancer Res, 70, 6670, 10.1158/0008-5472.CAN-09-4471

Cichowski, 2003, Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor, Genes Dev, 17, 449, 10.1101/gad.1054703

Dimri, 1995, A biomarker that identifies senescent human cells in culture and in aging skin in vivo, Proc Natl Acad Sci U S A, 92, 9363, 10.1073/pnas.92.20.9363

Messiaen, 2000, Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects, Hum Mutat, 15, 541, 10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N

Wimmer, 2006, Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients, Genes Chromosomes Cancer, 45, 265, 10.1002/gcc.20289

Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003

Forbes, 2011, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer, Nucleic Acids Res, 39, D945, 10.1093/nar/gkq929

Berger, 2012, Melanoma genome sequencing reveals frequent PREX2 mutations, Nature, 485, 502, 10.1038/nature11071

Hodis, 2012, A landscape of driver mutations in melanoma, Cell, 150, 251, 10.1016/j.cell.2012.06.024

Krauthammer, 2012, Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma, Nat Genet, 44, 1006, 10.1038/ng.2359

Thông tin
Thông tin xuất bản

Cancer Discovery

Tập 3 Số 3

338-349

Thông tin tác giả